Clinicopathological features and treatment outcomes for patients with metastatic triple-negative breast cancer

吴涛,王淑莲,金晶,刘跃平,王维虎,宋永文,余子豪,刘新帆,张江鹄

DOI: https://doi.org/10.3760/cma.j.issn.1004-4221.2014.03.001

2014-01-01

Abstract:Objective To analyze the clinicopathological features and survival of patients with metastatic triple-negative breast cancer (TNBC) and the value of locoregional treatment for metastatic TNBC.Methods A retrospective analysis was performed on the clinical features and treatment outcomes of 220 patients with metastatic TNBC admitted from 1998 to 2013.Of them,206 patients with stage Ⅰ-Ⅲ disease developed metastasis disease after treatment (186 patients undergoing modified radical mastectomy,14 patients undergoing breast-conserving surgery plus radiotherapy,5 patients undergoing breast-conserving surgery alone,and one patient not undergoing surgery; 196 patients receiving chemotherapy,and 88 patients receiving locoregional radiotherapy after modified radical mastectomy),and 14 patients presented stage Ⅳ disease (8 patients undergoing modified radical mastectomy,one patient undergoing segmental mastectomy,and 5 patients not undergoing surgery).Overall survival (OS) and progression-free survival were calculated by the Kaplan-Meier method; the log-rank test and univariate prognostic analysis were used to assess treatment outcomes.Results The most common metastatic sites were the lung followed by bones.Of all patients,182 (82.7％) developed visceral organs metastasis.Sixty-three (28.6％) developed metastasis to a single organ,whereas 182 (69.5％) with multiple metastatic disease and 4 patients were unclear.Most patients developed distant metastasis within 3 years after the initial diagnosis of TNBC,and only 6.4％ of all patients developed distant metastasis over 5 years later.With a median follow-up of 22 months,the 5-year OS was 25.0％,and the median survival time was 21 months.The 5-year OS of patients with single metastasis was 38.2％,compared with 17.5％ for those with multiple metastases (P =0.005).The 5-year OS of patients with visceral organ metastasis was 20.3％,compared with 56.2％ for those with metastasis in bones (P =0.049).For 63 patients with single metastasis,those receiving locoregional treatment with radiotherapy or surgery had a significantly increased OS compared with those receiving no locoregional treatment (48％ vs 29％,P =0.006).Conclusions Patients with metastatic TNBC usually present with visceral metastasis.Patients with single metastasis have a better outcomes than those with multiple metastases.Patients with metastasis in bones have a better autcomes than those with visceral organs involved.Locoregional treatment significantly improved the overall survival in patients with single metastasis.